ZIM Laboratories

ZIM Laboratories PEG

PEG Ratio (Price/Earnings-to-Growth) of ZIM Laboratories (ZIMLAB.NS) as of Oct 24, 2026.

PEG

-

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of ZIM Laboratories is 2026 - . PEG Ratio (Price/Earnings-to-Growth) of ZIM Laboratories was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ZIM Laboratories Stock analysis

What does ZIM Laboratories do? Zim Laboratories Ltd. develops, manufactures, and supplies oral solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) across therapeutic segments including central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology, and vitamins, minerals, and dietary supplements. The company's technological capabilities focus on drug release modification, solubility and stability enhancement, taste masking, and dosage form transformation. Its product offerings include finished formulations such as tablets, capsules, oral thin films, granules, pellets, taste-masked powders, and dry suspensions, alongside pre-formulation intermediates. The firm generates revenue through the supply of these pharmaceutical products to healthcare providers and distributors within the Indian market. The company's delivery solutions encompass product conceptualization, development, registration filing, manufacturing, and supply, targeting various therapeutic segments. Its differentiated generic formulations cater to specific medical needs, with a focus on innovation in drug delivery systems. Zim Laboratories Ltd. serves the Indian pharmaceutical market, supplying both finished products and pre-formulation intermediates to meet the demands of healthcare institutions and retail pharmacies. Zim Laboratories Ltd. operates as a pharmaceutical company based in Nagpur, Maharashtra, with 525 full-time employees. It develops and manufactures generic pharmaceutical products including oral solid dosage forms and pre-formulation intermediates. The company's revenue streams come from the sale of these products to customers in the healthcare sector, particularly within the Indian market, leveraging its technological capabilities in drug formulation and delivery. ZIM Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ZIM Laboratories stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) ZIM Laboratories since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s ZIM Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ZIM Laboratories

All Key Metrics — ZIM Laboratories